Novavax
World
Big pharma — Maximum earnings, minimum responsibilities

The COVID-19 pandemic has again exposed the true nature of capitalism with profit being the primary driver irrespective of the rising inequalities

World
Could Novavax’s COVID vaccine address some challenges in the current vaccination process?

Newsclick’s Prabir Purkayastha and immunologist Dr. Satyajit Rath discuss Covavax, the protein subunit-based vaccine manufactured by the US manufacturer Novavax

World
Covaxin trials: What 81% “interim efficacy” means

Bharat Biotech has claimed in a press release that its Covid-19 vaccine candidate, Covaxin, showed 81% efficacy in the “first interim analysis” of phase-3 trials.


    All text content published on peoplesdispatch.org is the property of Peoples Dispatch and is under a Creative Commons Attribution-ShareAlike 4.0 (CC BY-SA) license.
    For license to republish any audio, video or image content, please get in touch with the Peoples Dispatch Team.
    Share on Facebook Share
    Share on Twitter Tweet
    Share on Reddit Share
    Share on Whatsapp Share
    Send email Mail
    Print this Print